A method for monitoring the progression of an adrenoleukodystrophy in a subject suffering from adrenoleukodystrophy comprising determining in a sample from said subject a value selected from the group consisting of- the levels of sphingosine-1-phosphate,- the expression levels of sphingosine-2-phopshate kinase,- the expression levels sphingosine-1-phosphate receptor,- the expression levels of adiponectin,- the levels of at least one marker as defined in Table 1,- the levels of at least one marker as defined in Table 2,- the levels of at least one marker as defined in Table 3,- the levels of at least one marker as defined in Table 4,- the expression levels of at least one marker as defined in Table 5,- the levels of at least one marker as defined in Table 6,- the expression levels of at least one marker as defined in Table 7 and- the expression levels of at least one marker as defined in Table 8 wherein increased levels of sphingosine-1-phosphate, increased levels of sphingosine-2-phopshate kinase, increased levels of sphingosine-1-phosphate receptor, decreased expression levels of adiponectin, increased levels of at least one marker as defined in Table 1, decreased levels of at least one marker as defined in Table 2, increased levels of at least one marker as defined in Table 3, decreased levels of at least one marker as defined in Table 4, increased expression levels of at least one marker as defined in Table 5, increased levels of at least one marker as defined in Table 6, increased expression levels of at least one marker as defined in Table 7, and/or increased expression levels of at least one marker as defined in Table 8 with respect to a value determined in a sample from the same subject at an earlier time point is indicative of a worsening of the adrenoleukodystrophy or wherein decreased levels of sphingosine-1-phosphate, decreased levels of sphingosine-2-phopshate kinase, decreased levels of sphingosine-1-phosphate receptor, increased expression levels of adiponectin, decreased levels of at least one marker as defined in Table 1, increased levels of at least one marker as defined in Table 2, decreased levels of at least one marker as defined in Table 3, increased levels of at least one marker as defined in Table 4, decreased expression levels of at least one marker as defined in Table 5, decreased levels of at least one marker as defined in Table 6, decreased expression levels of at least one marker as defined in Table 7, and/or decreased expression levels of at least one marker as defined in Table 8 with respect to a value determined in a sample from the same subject at an earlier time point is indicative of an amelioration of the adrenoleukodystrophy
Gel-purified chemically synthesized RNAs were radiolabelled directly using T4 Polynucleotide Kinase (PNK) (NEB, M0201) and [- 32 P] ATP (Revvity, BLU035C005MC) in T4 PNK reaction buffer (NEB, B0201S) at 37 C for 12 h, then desalted using Micro Bio-Spin P-6 columns (Bio-Rad, 7326221) and gel-purified on a urea-polyacrylamide gel
For full details on how your data is collected, used and protected, please read our Privacy Policy.
La L-Carnitine LifeProse prsente sous forme de glules pratiques, faciles intgrer dans la routine quotidienne
